Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial [Gastrointestinal Cancer]

Conclusion
In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned.

Source: Journal of Clinical Oncology - August 2, 2016 Category: Cancer & Oncology Authors: Pavlakis, Sjoquist, Martin, Tsobanis, Yip, Kang, Bang, Alcindor, OCallaghan, Burnell, Tebbutt, Rha, Lee, Cho, Lipton, Wong, Strickland, Kim, Zalcberg, Simes, Goldstein Tags: Chemotherapy Gastrointestinal Cancer Source Type: research